What is Xenetic Biosciences Operating Cash Flow per Share?
Xenetic Biosciences's operating cash flow per share for the
three
months ended in Mar. 2024 was $-0.75.
Xenetic Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.72.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 26.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 48.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Xenetic Biosciences's Operating Cash Flow per Share or its related term are showing as below:
XBIO'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -259.9 Med: 36 Max: 62.2
Current: 26.1
During the past 13 years, Xenetic Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 62.20% per year. The lowest was -259.90% per year. And the median was 36.00% per year.
XBIO's 3-Year OCF Growth Rate is ranked better than 76.13% of 1240
companies
in the Biotechnology industry
Industry Median: 3.55
vs XBIO: 26.10
Xenetic Biosciences Operating Cash Flow per Share Historical Data
The historical data trend for Xenetic Biosciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Xenetic Biosciences Operating Cash Flow per Share Chart
Competitive Comparison of Xenetic Biosciences's Operating Cash Flow per Share
For the Biotechnology subindustry, Xenetic Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Price-to-Operating-Cash-Flow falls into.
Xenetic Biosciences Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Xenetic Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Xenetic Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenetic Biosciences (Xenetic Biosciences) Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBIO has been successfully added to your 